Alpha-Ketoglutarate Side Effects: What Studies Report

Alpha-ketoglutarate (AKG, also written 2-oxoglutarate) is a tricarboxylic acid cycle intermediate that appears in the literature as a metabolite, a cofactor for dioxygenase enzymes, and an experimental dietary compound. When readers look for "side effects," they are usually looking for a catalogue of documented harms in people. In the verified papers summarised below, that catalogue does not exist. What exists instead is a set of preclinical and mechanistic reports, a clinical report on anaplerotic therapy in a rare inherited metabolic disorder, a formulation-stability study, and reviews in which AKG-related metabolism is one element among many. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms, medication or supplementation.

What the Literature Base Looks Like

Safety statements are only as strong as the study designs behind them. Three design features determine how much a paper can say about side effects: whether it studied a living organism, whether the organism was human, and whether adverse events were collected as a pre-specified outcome. Most AKG papers fail at least one of these tests for the purpose of human safety.

• Cell and yeast models. These describe biochemistry, not tolerability. A metabolomics study in yeast reported oxidative stress and metabolic changes associated with local-anaesthetic-induced cell death, with tricarboxylic acid cycle metabolites among the profiled species (PMID 28236766).
• Rodent and livestock models. These can show organ-level effects and dietary tolerance, but species differences in amino acid and glutamate metabolism limit extrapolation, as a review of dietary L-glutamate and L-glutamine in poultry discussed when it addressed interorgan metabolism, nutritional impact and safety (PMID 34251641).
• Clinical reports in specific diseases. A study of anaplerotic therapy in propionic acidemia described the use of anaplerotic strategies in that inherited metabolic disorder (PMID 28712602), a context far removed from general supplementation in healthy adults.

Alpha-Ketoglutarate Adverse Events in Humans: What Studies Report

Within the verified set, no paper was designed as a dedicated human safety or tolerability trial of AKG, and none reported a frequency table of adverse events in healthy volunteers. Stated plainly: human adverse-event data for alpha-ketoglutarate supplementation are absent from this evidence base. That is an absence of evidence, which is different from evidence of safety and different from evidence of harm.

The closest clinical material is in two places. First, the report on anaplerotic therapy in propionic acidemia described therapeutic use of anaplerotic agents in patients with that disorder (PMID 28712602); disease-specific metabolic therapy does not generate a tolerability profile that transfers to people without the disorder. Second, a 2024 Cochrane systematic review of nutritional interventions for preventing and treating pressure ulcers examined supplementation approaches in clinical populations and characterised the certainty of the evidence as limited across comparisons (PMID 38345088). Reviews of this kind are useful precisely because they show how thin adverse-event reporting often is in nutrition trials; the review did not establish an AKG-specific side-effect profile.

Readers sometimes expect a list of common complaints such as gastrointestinal upset or taste aversion. Those complaints may well be plausible for any orally administered acid or salt, but plausibility is not data. Because no paper in the verified list quantified them for AKG, this page does not list them as reported effects.

Animal and Cell-Model Findings: What Studies Report

Preclinical papers describe biological activity, and activity is where questions about unintended effects begin. Researchers reported that dietary AKG delayed age-related fertility decline in mammalian models (PMID 33450127), an effect on reproductive ageing rather than a toxicity measure. In neurodegeneration models, the study of dietary AKG intake reported amelioration of alpha-synuclein pathology in mouse models of Parkinson's disease (PMID 37204481). Both papers describe intended or hypothesised benefits in animals; neither functions as a toxicology dossier, and neither reports human outcomes.

On the inflammation side, researchers reported that alpha-ketoglutarate suppressed the NF-κB-mediated inflammatory pathway and enhanced the PXR-regulated detoxification pathway in an experimental model (PMID 29262538). This is a mechanistic result with two faces: immune-pathway modulation and xenobiotic-handling modulation. Both are the kinds of activity that, in pharmacology generally, prompt follow-up questions about interactions — questions the verified literature has not answered for AKG in people.

Species and model context also matters for dose interpretation. Because none of the dose figures from these papers are reproduced here, readers should treat the animal work as qualitative: researchers administered AKG through the diet in the fertility and Parkinson's models (PMID 33450127, PMID 37204481), and dietary exposure in a rodent is not interchangeable with a capsule in a human.

Mechanistic Signals That Raise Safety Questions

Drug-metabolism pathways

Pregnane X receptor (PXR) is a nuclear receptor that governs expression of detoxification and drug-metabolising machinery. Researchers reported that AKG enhanced the PXR-regulated detoxification pathway alongside suppression of NF-κB signalling (PMID 29262538). In broader pharmacology, compounds that shift PXR-linked pathways are routinely evaluated for effects on the clearance of co-administered drugs. Whether that translates to measurable interactions with AKG in humans was not addressed in the verified papers, so the interaction question remains open rather than resolved.

AKG metabolism in cancer biology

AKG sits at a control point in mitochondrial metabolism, and that control point is under active investigation in oncology. A 2025 study reported that alpha-ketoglutarate dehydrogenase represented a therapeutic vulnerability in acute myeloid leukemia (PMID 39791576) — that is, inhibiting the enzyme that consumes AKG was explored as an anti-leukemic strategy. This paper is about targeting an enzyme in malignant cells, not about the safety of consuming AKG. It is included here because it illustrates why the AKG node is not metabolically inert: cancer-metabolism work shows that flux through this step influences cell fate, which is the sort of context in which researchers argue for caution and further study rather than reassurance.

Angiogenesis and vascular repair

Glutamine-derived carbon feeds AKG, and that flux appears in vascular biology. A 2025 study reported that defective endothelial glutaminolysis contributed to impaired angiogenesis and poor ischemic tissue repair in diabetes models (PMID 40405912). Effects on new blood-vessel formation are, in principle, double-edged — desirable in ischemic repair, undesirable in other settings — but the verified literature contains no human data on whether dietary AKG shifts angiogenesis in either direction.

Epigenetic enzymes

AKG-dependent dioxygenases participate in DNA and histone demethylation, which is why epigenetics papers touch this metabolite's territory. A 2025 study of prenatal arsenic exposure reported disrupted placental angiogenesis via altered epigenetic modification of the Pdgfb promoter (PMID 40440895). That study concerned a toxicant, not AKG supplementation; it is cited only to show that promoter methylation in developing tissue is biologically consequential and closely studied.

Pregnancy, Reproduction and Development: What Studies Report

The reproductive-ageing finding in mammals (PMID 33450127) is sometimes read as evidence that AKG is reproductively benign. It is not that kind of study: it reported delayed age-related fertility decline as an outcome of interest, not pregnancy safety, teratology or lactation endpoints. No paper in the verified set reported human pregnancy, fetal or paediatric safety data for AKG. Developmental toxicology for this compound is, on this evidence base, unreported.

Formulation, Stability and Quality Considerations in the Literature

Side-effect discussions often overlook the product itself. An accelerated stability and bioassay study of a new oral alpha-ketoglutarate formulation developed for treating cyanide poisoning reported on the formulation's stability characteristics and bioassay performance (PMID 24044407). Two points follow. First, AKG has been studied as a defined pharmaceutical preparation with stability testing, which is a different quality regime from unregulated products. Second, degradation and salt form are variables that pharmaceutical scientists measure deliberately, because what a preparation contains at the time of use is not necessarily what was formulated.

Where AKG Appears Inside Broader Reviews

A 2022 review of advances in the pathogenesis and therapeutic strategies for osteoporosis surveyed bone-metabolism mechanisms and candidate therapeutic approaches (PMID 35283172). Reviews like this map where metabolic targets sit within a disease field; they do not supply tolerability data for individual compounds, and the review did not report an AKG adverse-event profile.

Summary Table: Study Type and What It Can and Cannot Say

Gaps a Reader Should Notice

1. No dedicated human tolerability trial of AKG appears in the verified set, so no incidence rates of any complaint can be quoted.
2. No long-term human exposure data were reported, meaning chronic-use questions are unaddressed.
3. No human drug-interaction studies were reported, even though PXR-pathway modulation was described in an experimental model (PMID 29262538).
4. No pregnancy, lactation or paediatric safety data were reported for AKG in these papers.
5. No comparison between salt forms (for example calcium or arginine salts) on tolerability was reported, although formulation science has been applied to at least one oral preparation (PMID 24044407).

Anyone weighing this literature is weighing mechanism against silence. That is a legitimate description of the state of the field, and it is the reason this page reports absence explicitly rather than implying that a quiet literature is a clean one.

Related Learning on PeptideU

This page covers safety and adverse-event intent only. For the underlying biology — how AKG sits in the TCA cycle, what dioxygenase cofactor activity means, and how the ageing and metabolic literature developed — the PeptideU alpha-ketoglutarate course at /learn/alpha-ketoglutarate/ teaches the mechanism and study-design material in sequence, without duplicating the adverse-event summary here.

References

• Nutritional interventions for preventing and treating pressure ulcers (The Cochrane Database of Systematic Reviews, 2024)
• Advances in pathogenesis and therapeutic strategies for osteoporosis (Pharmacology & Therapeutics, 2022)
• α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia (Blood, 2025)
• Alpha-ketoglutarate suppresses the NF-κB-mediated inflammatory pathway and enhances the PXR-regulated detoxification pathway (Oncotarget, 2017)
• α-ketoglutarate delays age-related fertility decline in mammals (Aging Cell, 2021)
• Anaplerotic therapy in propionic acidemia (Molecular Genetics and Metabolism, 2017)
• Prenatal arsenic exposure disrupts placental angiogenesis by altering Pdgfb promoter epigenetic modification (Journal of Hazardous Materials, 2025)
• Defective Endothelial Glutaminolysis Contributes to Impaired Angiogenesis and Poor Ischemic Tissue Repair in Diabetes (Research, 2025)
• Dietary intake of α-ketoglutarate ameliorates α-synuclein pathology in mouse models of Parkinson's disease (Cellular and Molecular Life Sciences, 2023)
• Interorgan Metabolism, Nutritional Impacts, and Safety of Dietary L-Glutamate and L-Glutamine in Poultry (Advances in Experimental Medicine and Biology, 2021)
• Accelerated stability and bioassay of a new oral α-ketoglutarate formulation for treating cyanide poisoning (Pharmaceutical Biology, 2014)
• Oxidative stress, metabolomics profiling, and mechanism of local anesthetic induced cell death in yeast (Redox Biology, 2017)